The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms.
 
Alissa Cooper
Honoraria - Ideology Health; Intellisphere; MedStar Health; MJH Life Sciences; Physician's Education Resource, LLC
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Regeneron
Research Funding - Abbvie (Inst); Amgen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Sreenivasa Chandana
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Cardiff Oncology (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Zymeworks (Inst)
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BeiGene; Jazz Pharmaceuticals; Mirati Therapeutics; Novartis; Omega Therapeutics
Speakers' Bureau - Binaytara Foundation - Education Academy
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); InhibRx (Inst); Jacobus Pharmaceutical Company (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Poseida Therapeutics (Inst); SOPHiA Genetics (Inst)
 
Kyriakos Papadopoulos
Consulting or Advisory Role - AADi; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Alnylam (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Bristol-Myers Squibb/Celgene (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Frontier Medicines (Inst); Genmab (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Afshin Dowlati
No Relationships to Disclose
 
Ji-Youn Han
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sankyo/UCB Japan; Janssen; Lantern Pharma; Merck; Novartis; Oncovix; Takeda
Research Funding - Pfizer; Roche
 
Michael Michael
Honoraria - Astellas Pharma; Ipsen (Taiwan); Novartis; SAM NORDIC
Consulting or Advisory Role - Astellas Pharma; BeiGene (Australia); Ipsen; Isotopen Technologien; Merck; MSD; PanTher Therapeutics
Research Funding - Ipsen; Ipsen (Australia); Merck Serono
Travel, Accommodations, Expenses - Ipsen; Ipsen; Novartis
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Amgen; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; BMS; Boehringer Ingelheim; Bridgebio; CJ bioscience; Cyrus therapeutics; Cyrus therapeutics; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Guardant Health; Harpoon Therapeutics; J INTS Bio; Janssen; Kanaph Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Therapex Co., Ltd; Yuhan
Research Funding - AstraZeneca; Champions Oncology; CJ bioscience; Cyrus Therapeutics; Dong-A ST; GI Innovation; ImmuneOncia; J Ints Bio; Janssen; MSD; Therapex; Vertical Bio AG; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Chong Kun Dang Pharmaceutical; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Merck KGaA; Novartis; Regeneron; Roche; Samsung Bioepis; Takeda
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Enliven Therapeutics (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Yuhan (Inst)
 
Anne Chiang
Consulting or Advisory Role - Abbvie; Abbvie; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daichi; Flatiron Health; Fosun Pharma; Genentech; Genentech; Genentech; Genentech/Roche; Janssen Oncology; Jazz Pharmaceuticals; Jazz Pharmaceuticals; regeneron; Sanofi/Regeneron; Zai Lab
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx; Zai Lab
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Janssen Oncology; Medison; Merck Serono; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Noura Choudhury
Consulting or Advisory Role - Abbvie; Abbvie; G1 Therapeutics; Harpoon therapeutics; Lilly; Merck; Sanofi
Research Funding - Abbvie (Inst); abbvie (Inst); Amgen (Inst); Harpoon therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Wolters Kluwer (Pocket Oncology).
 
Wallace Akerley
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Other Relationship - Lilly
 
Sunil Babu
Employment - Fort Wayne Medical Oncology & Hematology
Leadership - Exigent Research
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology; Lutheran hospital (I)
Honoraria - Cornerstone Healthcare Group; Janssen Scientific Affairs; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Cornerstone Specialty Network; E.R. Squibb Sons, LLC; Janssen Oncology; Kite, a Gilead company; Novartis; Taiho Oncology
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Aptose Biosciences (Inst); Aptose Biosciences (Inst); argenx (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Scholar Rock (Inst); Syndax (Inst); Takeda (Inst); TG Therapeutics (Inst); Torl Biotherapeutics (Inst)
Travel, Accommodations, Expenses - BeiGene; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics
 
Wijith Munasinghe
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Randy Robinson
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Fred Kohlhapp
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Pooja Hingorani
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
Lauren Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; Arrowhead Pharmaceuticals; AstraZeneca; BeiGene; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Merck Sharp & Dohme Corp.; Novartis; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas (Priority date: 3/3/2021); Molecular subtyping of small cell lung cancer to predict therapeutic responses (US Patent No.: 11,732,306; Priority Date 9/3/2019; Issue Date 8/22/2023)